13D Filing: Orbimed Israel Biofund GP Limited Partnership and Novus Therapeutics Inc. (NVUS)

Page 2 of 9 – SEC Filing

SCHEDULE 13D
CUSIP No. 67011N105
Page 2 of 10 Pages
1
NAME OF REPORTING PERSONS
OrbiMed Israel BioFund GP Limited Partnership
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) o
(b) o
3
SEC USE ONLY
4
SOURCE OF FUNDS (See Instructions)
N/A
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
o
6
CITIZENSHIP OR PLACE OF ORGANIZATION
State of Israel
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
7
SOLE VOTING POWER
0
8
SHARED VOTING POWER
2,537,110
9
SOLE DISPOSITIVE POWER
0
10
SHARED DISPOSITIVE POWER
2,537,110
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,537,110
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
o
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
36.2% (1)
14
TYPE OF REPORTING PERSON (See Instructions)
PN
(1)
This percentage is calculated based upon approximately 7,000,000 shares of common stock, par value $0.001 per share (the “Shares”), outstanding of Novus Therapeutics, Inc., a Delaware corporation (the “Issuer”), as set forth in the Issuer’s Current Report on Form 8-K filed with the Securities Exchange Commission on May 15, 2017.

Follow Eledon Pharmaceuticals Inc. (NASDAQ:ELDN)